Biotie SYN120 clinical study Phase 1 started
The trial of healthy volunteers is being conducted by Dr Dean Wong at the Johns Hopkins University School of Medicine in the United States to determine occupancy of the 5-HT6 receptor in the brain following different doses of SYN120. This will help to establish the appropriate dose for subsequent Phase 2 trials.
"This is an important step in our development program for SYN120, which we believe is a potential best-in-class compound targeting the 5HT6 receptor with significant potential to help patients suffering from Alzheimer's disease and other diseases affecting cognition," commented Dr Stephen Bandak, Biotie's Chief Medical Officer. "We are particularly pleased to collaborate with the leading PET center for this type of research in the United States."
Results from the study are expected in the first half of 2012.
SYN120 is a potent, selective and orally bioavailable 5HT6 receptor antagonist, exclusively targeting regions in the brain associated with memory function. SYN120 has been shown to enhance cognition in various preclinical models.
The compound was discovered at Roche and is being developed by Biotie under a licensing agreement. SYN120 has completed single and multiple-ascending dose studies in Phase 1. Roche retains an opt-in right on the 5HT6 program on completion of the imaging study.